This clinical trial, sponsored by Northwestern University, investigates the pharmacokinetics of pemetrexed disodium in patients with leptomeningeal metastases, a challenging condition with limited treatment options. The study aims to elucidate the drug's effectiveness and safety profile in this patient population, potentially positioning pemetrexed as a viable treatment for leptomeningeal metastases. Given the increasing incidence of brain metastases and leptomeningeal disease in cancer patients, successful outcomes could enhance pemetrexed's market potential. The collaboration with the National Cancer Institute (NCI) may also facilitate further research and development opportunities. Competitive implications include the need to monitor other therapies targeting similar patient populations, particularly those in late-stage development or with established market presence.